The Cancer Clinical Trials Office will present its Fourteenth Annual Oncology Clinical Research Forum on Friday, June 21, from 8 a.m. to 3:30 p.m. in the Clark Center Auditorium.

Please confirm your attendance by completing the below Qualtrics Survey by 5pm Friday, May 17, and mark your calendars.

Registration Link:
https://stanforduniversity.qualtrics.com/jfe/form/SV_9H29JTD3JRQOp6t

IMPORTANT: Any “hold” on your calendar for the Oncology Forum does not confirm your attendance.You MUST fill out a registration form, linked above, to confirm if you will be attending or not.

We are excited to announce that the focus of this year’s Forum is Celebrating Novel Modalities and Approaches in Cancer Treatment at Stanford. 

Novel modalities and approaches such as Theranostics, CAR T Cell Therapy, and Total 17 will be covered from a scientific, operational and patient perspective. The importance of these novel therapies—including all the cancer clinical trials conducted at Stanford—and how they support our Comprehensive Cancer Center status will also be a focus of the Forum.   

Theranostics – A radioactive atom attached to small molecules to finely target disease (currently conducting research in PNET and prostate, but soon expanding to melanoma and lung).

Car T Cell Therapy – A type of treatment in which a patient’s T cells (a type of immune system cell) are changed in the laboratory so they will attack cancer cells.

Total 17 – Application of the most comprehensive risk classification to date, combining blast cell immunophenotype and leukemia-specific genomic features with presenting clinical characteristics and early treatment minimal residual disease (MRD) response in order to maximize leukemia control while reducing adverse effects.

If you are a Principal Investigator conducting cancer clinical trials, you are encouraged to recommend this free course to your research staff. The final agenda will be provided the day of the forum.